Vanda Pharmaceuticals Inc. (VNDA)
USD 4.15
(-5.03%)
USD 4.15
(-5.03%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 648.44 Million USD | 2.24% |
| 2022 | 634.24 Million USD | 6.81% |
| 2021 | 593.79 Million USD | 11.31% |
| 2020 | 533.45 Million USD | 10.28% |
| 2019 | 483.74 Million USD | 45.65% |
| 2018 | 332.13 Million USD | 61.68% |
| 2017 | 205.42 Million USD | -2.35% |
| 2016 | 210.37 Million USD | -1.26% |
| 2015 | 213.05 Million USD | 24.08% |
| 2014 | 171.7 Million USD | 19.78% |
| 2013 | 143.34 Million USD | 5.83% |
| 2012 | 135.44 Million USD | -25.83% |
| 2011 | 182.61 Million USD | -14.3% |
| 2010 | 213.1 Million USD | -5.59% |
| 2009 | 225.71 Million USD | 352.03% |
| 2008 | 49.93 Million USD | -48.45% |
| 2007 | 96.86 Million USD | 167.13% |
| 2006 | 36.26 Million USD | 1.42% |
| 2005 | 35.75 Million USD | 101.4% |
| 2004 | 17.75 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 651.37 Million USD | -0.2% |
| 2024 Q1 | 652.68 Million USD | 0.65% |
| 2023 Q4 | 648.44 Million USD | 1.07% |
| 2023 Q2 | 641.68 Million USD | -0.44% |
| 2023 Q1 | 644.53 Million USD | 1.62% |
| 2023 FY | 648.44 Million USD | 2.24% |
| 2023 Q3 | 641.6 Million USD | -0.01% |
| 2022 FY | 634.24 Million USD | 6.81% |
| 2022 Q3 | 621.78 Million USD | 2.08% |
| 2022 Q4 | 634.24 Million USD | 2.0% |
| 2022 Q1 | 603.55 Million USD | 1.64% |
| 2022 Q2 | 609.1 Million USD | 0.92% |
| 2021 Q1 | 543.19 Million USD | 1.82% |
| 2021 Q4 | 593.79 Million USD | 2.42% |
| 2021 FY | 593.79 Million USD | 11.31% |
| 2021 Q2 | 567.64 Million USD | 4.5% |
| 2021 Q3 | 579.76 Million USD | 2.14% |
| 2020 Q1 | 488.52 Million USD | 0.99% |
| 2020 Q3 | 515.9 Million USD | 1.83% |
| 2020 Q4 | 533.45 Million USD | 3.4% |
| 2020 Q2 | 506.63 Million USD | 3.71% |
| 2020 FY | 533.45 Million USD | 10.28% |
| 2019 FY | 483.74 Million USD | 45.65% |
| 2019 Q2 | 372.48 Million USD | 6.07% |
| 2019 Q3 | 474.44 Million USD | 27.37% |
| 2019 Q4 | 483.74 Million USD | 1.96% |
| 2019 Q1 | 351.16 Million USD | 5.73% |
| 2018 Q4 | 332.13 Million USD | 6.47% |
| 2018 Q3 | 311.93 Million USD | 2.97% |
| 2018 Q2 | 302.92 Million USD | -4.53% |
| 2018 Q1 | 317.31 Million USD | 54.47% |
| 2018 FY | 332.13 Million USD | 61.68% |
| 2017 Q1 | 204.72 Million USD | -2.69% |
| 2017 Q3 | 205.7 Million USD | -2.36% |
| 2017 Q2 | 210.67 Million USD | 2.91% |
| 2017 Q4 | 205.42 Million USD | -0.14% |
| 2017 FY | 205.42 Million USD | -2.35% |
| 2016 Q4 | 210.37 Million USD | 0.93% |
| 2016 FY | 210.37 Million USD | -1.26% |
| 2016 Q3 | 208.44 Million USD | 3.17% |
| 2016 Q2 | 202.03 Million USD | -2.27% |
| 2016 Q1 | 206.74 Million USD | -2.96% |
| 2015 Q1 | 213.64 Million USD | 24.42% |
| 2015 Q4 | 213.05 Million USD | -3.4% |
| 2015 Q2 | 223.69 Million USD | 4.71% |
| 2015 FY | 213.05 Million USD | 24.08% |
| 2015 Q3 | 220.54 Million USD | -1.41% |
| 2014 Q1 | 120.98 Million USD | -15.6% |
| 2014 FY | 171.7 Million USD | 19.78% |
| 2014 Q2 | 86.17 Million USD | -28.77% |
| 2014 Q4 | 171.7 Million USD | 116.87% |
| 2014 Q3 | 79.17 Million USD | -8.12% |
| 2013 Q3 | 155.09 Million USD | 32.61% |
| 2013 FY | 143.34 Million USD | 5.83% |
| 2013 Q4 | 143.34 Million USD | -7.57% |
| 2013 Q2 | 116.95 Million USD | -6.54% |
| 2013 Q1 | 125.13 Million USD | -7.61% |
| 2012 FY | 135.44 Million USD | -25.83% |
| 2012 Q1 | 172.59 Million USD | -5.49% |
| 2012 Q2 | 160.83 Million USD | -6.81% |
| 2012 Q3 | 149.8 Million USD | -6.86% |
| 2012 Q4 | 135.44 Million USD | -9.59% |
| 2011 Q1 | 209.33 Million USD | -1.77% |
| 2011 Q4 | 182.61 Million USD | -6.7% |
| 2011 Q3 | 195.73 Million USD | -3.78% |
| 2011 FY | 182.61 Million USD | -14.3% |
| 2011 Q2 | 203.43 Million USD | -2.82% |
| 2010 Q2 | 222.88 Million USD | -1.34% |
| 2010 Q3 | 217.35 Million USD | -2.48% |
| 2010 FY | 213.1 Million USD | -5.59% |
| 2010 Q4 | 213.1 Million USD | -1.96% |
| 2010 Q1 | 225.92 Million USD | 0.09% |
| 2009 Q3 | 38.3 Million USD | -15.14% |
| 2009 FY | 225.71 Million USD | 352.03% |
| 2009 Q2 | 45.14 Million USD | -1.49% |
| 2009 Q1 | 45.82 Million USD | -8.22% |
| 2009 Q4 | 225.71 Million USD | 489.19% |
| 2008 Q4 | 49.93 Million USD | -12.51% |
| 2008 Q1 | 80.39 Million USD | -17.0% |
| 2008 Q3 | 57.07 Million USD | -18.77% |
| 2008 FY | 49.93 Million USD | -48.45% |
| 2008 Q2 | 70.25 Million USD | -12.61% |
| 2007 Q4 | 96.86 Million USD | -15.69% |
| 2007 Q2 | 125.31 Million USD | -6.6% |
| 2007 Q1 | 134.16 Million USD | 270.01% |
| 2007 FY | 96.86 Million USD | 167.13% |
| 2007 Q3 | 114.88 Million USD | -8.33% |
| 2006 Q1 | 25.18 Million USD | -29.55% |
| 2006 FY | 36.26 Million USD | 1.42% |
| 2006 Q3 | 47.28 Million USD | -27.0% |
| 2006 Q2 | 64.76 Million USD | 157.14% |
| 2006 Q4 | 36.26 Million USD | -23.31% |
| 2005 Q4 | 35.75 Million USD | 0.0% |
| 2005 FY | 35.75 Million USD | 101.4% |
| 2004 FY | 17.75 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 56.425% |
| Alkermes plc | 2.13 Billion USD | 69.645% |
| Agenus Inc. | 313.91 Million USD | -106.567% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 83.069% |
| Aptorum Group Limited | 20.64 Million USD | -3041.653% |
| Ardelyx, Inc. | 297.57 Million USD | -117.905% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 15.298% |
| Bicycle Therapeutics plc | 595.34 Million USD | -8.919% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -779.813% |
| ChromaDex Corporation | 54.96 Million USD | -1079.754% |
| Chimerix, Inc. | 212.77 Million USD | -204.755% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2193.545% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -47.049% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 70.916% |
| Precision BioSciences, Inc. | 159.78 Million USD | -305.83% |
| Dyadic International, Inc. | 8.21 Million USD | -7789.298% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1942.974% |
| Fortress Biotech, Inc. | 167.52 Million USD | -287.068% |
| Lantern Pharma Inc. | 43.64 Million USD | -1385.625% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -301.916% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -4369.951% |
| Incyte Corporation | 6.78 Billion USD | 90.439% |
| IO Biotech, Inc. | 150.71 Million USD | -330.234% |
| Jaguar Health, Inc. | 50.76 Million USD | -1177.387% |
| Novavax, Inc. | 1.85 Billion USD | 65.05% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -70.46% |
| Opthea Limited | 188.79 Million USD | -243.469% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 22.162% |
| ContextLogic Inc. | 423 Million USD | -53.296% |
| MiMedx Group, Inc. | 239.04 Million USD | -171.26% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -273.254% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -12443.085% |
| NextCure, Inc. | 129.41 Million USD | -401.043% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1101.972% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1665.471% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1907.492% |
| Vaxcyte, Inc. | 1.4 Billion USD | 53.943% |
| PDS Biotechnology Corporation | 59.39 Million USD | -991.832% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -1.232% |
| Pharming Group N.V. | 462.85 Million USD | -40.096% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1576.422% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -3.164% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3326.607% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3326.607% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -292.233% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1331.846% |
| Acelyrin, Inc. | 742.69 Million USD | 12.69% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -9744.952% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -10027.128% |
| Summit Therapeutics Inc. | 202.94 Million USD | -219.509% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -771.864% |
| Senti Biosciences, Inc. | 119.48 Million USD | -442.7% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -183.978% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -285.577% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -7747.513% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -13483.4% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -38.204% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -424.403% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -135.84% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -37.137% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -6317.021% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -202.295% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -57174.641% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -56.688% |
| Immix Biopharma, Inc. | 19.92 Million USD | -3154.378% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -75.242% |
| MEI Pharma, Inc. | 41.37 Million USD | -1467.227% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1900.987% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -90.271% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -453.158% |
| Fortress Biotech, Inc. | 167.52 Million USD | -287.068% |
| Precigen, Inc. | 151.04 Million USD | -329.308% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1806.167% |
| AlloVir, Inc. | 190.79 Million USD | -239.86% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -72.251% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -28.095% |
| ImmuCell Corporation | 43.8 Million USD | -1380.183% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 0.135% |
| Onconetix, Inc. | 88.82 Million USD | -630.049% |
| PureTech Health plc | 693.97 Million USD | 6.561% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -563.807% |
| Elevation Oncology, Inc. | 89.09 Million USD | -627.84% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -10355.337% |
| Seer, Inc. | 436.26 Million USD | -48.633% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -694.686% |
| Innoviva, Inc. | 1.24 Billion USD | 47.854% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -389.673% |
| ESSA Pharma Inc. | 149.12 Million USD | -334.838% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1330.914% |
| GT Biopharma, Inc. | 14.1 Million USD | -4495.932% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -110.606% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -168.28% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -37.408% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1179.05% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -581.049% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -102568.195% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -14.496% |
| Aptose Biosciences Inc. | 12.92 Million USD | -4917.897% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -2832.222% |
| Soligenix, Inc. | 9.79 Million USD | -6518.541% |
| Century Therapeutics, Inc. | 360.69 Million USD | -79.777% |
| Kura Oncology, Inc. | 448.93 Million USD | -44.44% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -138.267% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -3649.292% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -484.647% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -216.079% |
| Autolus Therapeutics plc | 375.38 Million USD | -72.742% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -157.69% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -82.565% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1219.792% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 1.92% |
| GRI Bio, Inc. | 2.95 Million USD | -21836.401% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -6014.344% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -280.283% |
| IGM Biosciences, Inc. | 423.41 Million USD | -53.147% |
| INmune Bio, Inc. | 57 Million USD | -1037.594% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -191.426% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -672.493% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2382.841% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -9320.625% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -761.989% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -340.343% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -291.797% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -2.992% |
| Verastem, Inc. | 149.71 Million USD | -333.108% |
| Abeona Therapeutics Inc. | 64 Million USD | -913.156% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -26.61% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -319.819% |
| Histogen Inc. | 19.07 Million USD | -3299.78% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -2762.848% |
| Surrozen, Inc. | 46.08 Million USD | -1307.205% |
| Organovo Holdings, Inc. | 6.34 Million USD | -10113.262% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -14949.83% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -350.222% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -5394.323% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -761.508% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -7511.468% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -78.649% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -3483.651% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -51.01% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -5041.567% |
| Apollomics, Inc. | 55.38 Million USD | -1070.744% |
| Amarin Corporation plc | 831.68 Million USD | 22.033% |
| Mesoblast Limited | 669.15 Million USD | 3.095% |
| Turnstone Biologics Corp. | 112.81 Million USD | -474.782% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -12.624% |
| Synaptogenix, Inc. | 31.11 Million USD | -1984.1% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -5222.062% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -18.315% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -10942.425% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -8728.127% |
| Exelixis, Inc. | 2.94 Billion USD | 77.962% |
| Better Therapeutics, Inc. | 22.94 Million USD | -2726.309% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -77.879% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 17.787% |
| NLS Pharmaceutics AG | 1.84 Million USD | -35014.567% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -8027.206% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -4312.657% |
| Gritstone bio, Inc. | 177.76 Million USD | -264.766% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -579.849% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -3530.222% |
| Avid Bioservices, Inc. | 336.55 Million USD | -92.669% |
| Insmed Incorporated | 1.32 Billion USD | 51.239% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -6634.698% |
| MediWound Ltd. | 66.45 Million USD | -875.699% |
| OmniAb, Inc. | 401.98 Million USD | -61.31% |
| Alector, Inc. | 621.82 Million USD | -4.28% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -80.825% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -11957.27% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1043.795% |
| Zai Lab Limited | 1.03 Billion USD | 37.427% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -35.528% |
| Aura Biosciences, Inc. | 255.07 Million USD | -154.215% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 13.545% |
| Immunic, Inc. | 54.29 Million USD | -1094.202% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -143.569% |
| Veracyte, Inc. | 1.13 Billion USD | 43.01% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -5384.665% |
| FibroGen, Inc. | 423.52 Million USD | -53.104% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -18358.298% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -13589.974% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -11842.953% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 94.309% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -7264.452% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -25.314% |
| TG Therapeutics, Inc. | 329.58 Million USD | -96.743% |
| Galecto, Inc. | 38.22 Million USD | -1596.288% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2161.264% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 85.118% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -175.458% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -2510.257% |
| XBiotech Inc. | 227.24 Million USD | -185.351% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -579.849% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -354.727% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -126.794% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -407.113% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -69.749% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 56.51% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -77.732% |
| Vaxxinity, Inc. | 44.35 Million USD | -1361.998% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -25.433% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -3384.489% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -112.568% |
| NexImmune, Inc. | 8.59 Million USD | -7445.309% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -5951.596% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -3685.982% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.04% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -2827.345% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -165206.617% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -274.109% |
| Ainos, Inc. | 31.84 Million USD | -1936.442% |
| Pluri Inc. | 39.52 Million USD | -1540.499% |
| Prothena Corporation plc | 696.38 Million USD | 6.884% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -129.442% |
| Celularity Inc. | 143.88 Million USD | -350.653% |
| Rallybio Corporation | 115.62 Million USD | -460.837% |
| Cue Biopharma, Inc. | 61.53 Million USD | -953.86% |
| MeiraGTx Holdings plc | 458.16 Million USD | -41.529% |
| Omeros Corporation | 378.26 Million USD | -71.423% |
| Humacyte, Inc. | 128.22 Million USD | -405.713% |
| Immunocore Holdings plc | 597 Million USD | -8.616% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1974.411% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -846.213% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 38.2% |
| CalciMedica, Inc. | 12.18 Million USD | -5221.625% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -155.644% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -279.409% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -108.478% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -14.707% |
| Pulmatrix, Inc. | 33.95 Million USD | -1809.535% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2288.713% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -360.35% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 50.157% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -398.076% |
| Cytokinetics, Incorporated | 824.31 Million USD | 21.336% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2969.829% |
| Nutriband Inc. | 7.51 Million USD | -8526.137% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -721.288% |
| Vor Biopharma Inc. | 209.82 Million USD | -209.034% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 91.022% |
| Evogene Ltd. | 51.1 Million USD | -1168.938% |
| ProKidney Corp. | 420.55 Million USD | -54.188% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1082.573% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -6711.146% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -18.679% |
| CorMedix Inc. | 82.05 Million USD | -690.203% |
| BioLineRx Ltd. | 63.92 Million USD | -914.376% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -61.076% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2199.433% |
| Atai Life Sciences N.V. | 293.47 Million USD | -120.95% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -297.5% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -408.908% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -15.375% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -570.437% |
| MediciNova, Inc. | 66.26 Million USD | -878.482% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -637.299% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -14431.308% |
| GeoVax Labs, Inc. | 9.28 Million USD | -6885.077% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -10.235% |
| Biomea Fusion, Inc. | 199.92 Million USD | -224.338% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 65.929% |
| Mereo BioPharma Group plc | 66.49 Million USD | -875.112% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -33.673% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -5.802% |
| Absci Corporation | 234.48 Million USD | -176.544% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -8764.525% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -90.779% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -292.799% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -23.202% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -133.51% |
| Allakos Inc. | 243.61 Million USD | -166.18% |
| Imunon, Inc. | 21.91 Million USD | -2858.472% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -151.632% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -4.332% |
| BioAtla, Inc. | 119.65 Million USD | -441.911% |
| NLS Pharmaceutics AG | 1.84 Million USD | -35014.567% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -20037.888% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -0.872% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -575.916% |
| XOMA Corporation | 234.3 Million USD | -176.755% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -193.1% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -415.273% |
| aTyr Pharma, Inc. | 122.06 Million USD | -431.216% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -321.33% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -11.748% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -32.22% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -486.988% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -4177.998% |
| Akari Therapeutics, Plc | 4.35 Million USD | -14789.552% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3705.995% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 62.589% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -20926.036% |
| UroGen Pharma Ltd. | 178.31 Million USD | -263.657% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -37.75% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -116585.711% |
| Orgenesis Inc. | 14.55 Million USD | -4356.02% |
| Entera Bio Ltd. | 11.76 Million USD | -5411.602% |
| GH Research PLC | 226.3 Million USD | -186.54% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1085.578% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -503.559% |
| Xencor, Inc. | 952.69 Million USD | 31.936% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -8230.666% |
| Replimune Group, Inc. | 487.72 Million USD | -32.953% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -7934.108% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -20926.036% |
| Portage Biotech Inc. | 7.77 Million USD | -8235.776% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -14431.308% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -134.14% |
| OncoCyte Corporation | 74.89 Million USD | -765.833% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -31791.83% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -11105.806% |
| Purple Biotech Ltd. | 44.3 Million USD | -1363.681% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1800.135% |
| scPharmaceuticals Inc. | 94.47 Million USD | -586.332% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -3493.469% |
| HilleVax, Inc. | 344.43 Million USD | -88.262% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -20316.877% |
| Tharimmune, Inc. | 10.94 Million USD | -5823.778% |
| Genprex, Inc. | 10.67 Million USD | -5976.889% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -30.682% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -573.69% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -26628.772% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -15467.139% |
| OKYO Pharma Limited | 1.54 Million USD | -41971.962% |
| Savara Inc. | 177.56 Million USD | -265.187% |
| Curis, Inc. | 77.28 Million USD | -739.057% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2946.863% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -913.999% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -7919.293% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -3247.478% |
| BeiGene, Ltd. | 5.8 Billion USD | 88.83% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -5228.622% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 68.953% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -81.153% |
| Erasca, Inc. | 395.29 Million USD | -64.039% |
| bluebird bio, Inc. | 619.16 Million USD | -4.729% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -14898.488% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 90.522% |
| DBV Technologies S.A. | 182.98 Million USD | -254.366% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -14898.488% |
| Moderna, Inc. | 18.42 Billion USD | 96.481% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -3459.532% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -5496.755% |
| Molecular Templates, Inc. | 35.38 Million USD | -1732.631% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -368.983% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 17.806% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -113.475% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -523.824% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -39.262% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -106.88% |
| MacroGenics, Inc. | 306.82 Million USD | -111.342% |
| RenovoRx, Inc. | 1.46 Million USD | -44131.924% |
| Adicet Bio, Inc. | 207.29 Million USD | -212.81% |
| Prime Medicine, Inc. | 193.85 Million USD | -234.504% |
| Aditxt, Inc. | 44.57 Million USD | -1354.608% |
| Adagene Inc. | 115.72 Million USD | -460.31% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -14457.981% |
| Quantum-Si incorporated | 298.25 Million USD | -117.415% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 56.406% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -8311.333% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -84.593% |
| SciSparc Ltd. | 11.18 Million USD | -5698.963% |
| Vericel Corporation | 353.65 Million USD | -83.353% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -5209.594% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1039.601% |
| Generation Bio Co. | 374.75 Million USD | -73.029% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -154.624% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -308.938% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -89.955% |
| Invivyd, Inc. | 229.18 Million USD | -182.938% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 23.169% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -5228.49% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -255.524% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -3074.892% |
| 2seventy bio, Inc. | 565.42 Million USD | -14.682% |
| ADMA Biologics, Inc. | 329.18 Million USD | -96.985% |
| Clene Inc. | 52.34 Million USD | -1138.876% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -1004.022% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -399.207% |
| GeoVax Labs, Inc. | 9.28 Million USD | -6885.077% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 0.804% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -525.84% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -397.323% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -564.712% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -813.334% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -167.34% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 66.918% |
| Evaxion Biotech A/S | 12.88 Million USD | -4931.105% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -157.256% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 13.85% |
| Trevena, Inc. | 40.6 Million USD | -1496.946% |
| Surrozen, Inc. | 46.08 Million USD | -1307.205% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -187.102% |
| Cingulate Inc. | 3.49 Million USD | -18472.301% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -3799.453% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -887.121% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -5449.514% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -141.489% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 13.421% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -415.076% |
| Clearmind Medicine Inc. | 4.32 Million USD | -14894.951% |
| Kronos Bio, Inc. | 213.27 Million USD | -204.034% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -305.823% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -7474.694% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -75.972% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2963.059% |
| ImmunityBio, Inc. | 504.45 Million USD | -28.543% |
| Korro Bio, Inc. | 221.66 Million USD | -192.534% |
| Kineta, Inc. | 10.28 Million USD | -6207.169% |
| BioVie Inc. | 25.2 Million USD | -2472.323% |
| Codexis, Inc. | 136.56 Million USD | -374.835% |
| Celularity Inc. | 143.88 Million USD | -350.653% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -2.06% |
| Celcuity Inc. | 191.21 Million USD | -239.108% |
| Virax Biolabs Group Limited | 5.48 Million USD | -11724.283% |
| Cibus, Inc. | 544.41 Million USD | -19.109% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -415.068% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3056.347% |
| IN8bio, Inc. | 33.7 Million USD | -1823.641% |
| Kodiak Sciences Inc. | 479.37 Million USD | -35.269% |
| Annexon, Inc. | 297.67 Million USD | -117.836% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -274.799% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -371.699% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2988.839% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 78.314% |
| Eyenovia, Inc. | 28.77 Million USD | -2153.141% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -181.285% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -8876.19% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -964.308% |
| Arcellx, Inc. | 825.13 Million USD | 21.414% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -694.297% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -40.271% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -2008.748% |
| Moolec Science SA | 24.05 Million USD | -2596.072% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -109.09% |
| Geron Corporation | 394.07 Million USD | -64.547% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -537.538% |
| Royalty Pharma plc | 16.38 Billion USD | 96.042% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -8.987% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -9170.295% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -5291.394% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -186.844% |
| Humacyte, Inc. | 128.22 Million USD | -405.713% |
| Structure Therapeutics Inc. | 482.01 Million USD | -34.526% |
| 89bio, Inc. | 596.26 Million USD | -8.75% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -157.162% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -34950.811% |
| Genelux Corporation | 27.89 Million USD | -2224.741% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -625.3% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -182.632% |
| Notable Labs, Ltd. | 19.54 Million USD | -3218.356% |
| Liquidia Corporation | 120.43 Million USD | -438.433% |
| Mustang Bio, Inc. | 17.74 Million USD | -3554.83% |
| Immunovant, Inc. | 666.71 Million USD | 2.741% |
| Quantum-Si incorporated | 298.25 Million USD | -117.415% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -349.055% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1097.267% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -269.385% |
| Acasti Pharma Inc. | 73.3 Million USD | -784.638% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -14144.288% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2382.841% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 32.79% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -12394.224% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -2746.407% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1156.594% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -258.867% |
| PepGen Inc. | 143.05 Million USD | -353.29% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1596.732% |
| United Therapeutics Corporation | 7.16 Billion USD | 90.952% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -3279.932% |
| Solid Biosciences Inc. | 164.93 Million USD | -293.139% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -10942.425% |
| Immuneering Corporation | 102.58 Million USD | -532.103% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -14949.83% |
| Silo Pharma, Inc. | 7.74 Million USD | -8271.136% |
| Belite Bio, Inc | 94.64 Million USD | -585.15% |
| XOMA Corporation | 234.3 Million USD | -176.755% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -178.076% |
| Bionomics Limited | 27.64 Million USD | -2245.249% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -61.543% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -503.829% |
| uniQure N.V. | 831.68 Million USD | 22.033% |
| Cassava Sciences, Inc. | 151.66 Million USD | -327.553% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -14457.981% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -136.756% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1563.52% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -15820.006% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1660.582% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -8876.19% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -18358.298% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -5385.492% |
| Altimmune, Inc. | 210.64 Million USD | -207.843% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 16.64% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -503.829% |
| Compugen Ltd. | 121.33 Million USD | -434.426% |
| Peak Bio, Inc. | 2.59 Million USD | -24874.436% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -276.285% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1141.984% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -89.681% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1764.78% |
| Zura Bio Limited | 100.84 Million USD | -543.019% |
| PolyPid Ltd. | 15.37 Million USD | -4118.319% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -443.601% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1764.78% |
| Instil Bio, Inc. | 325.63 Million USD | -99.134% |
| argenx SE | 4.54 Billion USD | 85.725% |
| Immunome, Inc. | 148.54 Million USD | -336.542% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -313.348% |
| Verona Pharma plc | 308.12 Million USD | -110.448% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -645.685% |
| Shattuck Labs, Inc. | 159.56 Million USD | -306.382% |
| CervoMed Inc. | 9.97 Million USD | -6402.268% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -244.08% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -5594.064% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -261.439% |
| Moolec Science SA | 24.05 Million USD | -2596.072% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -10499.789% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -274.941% |
| AnaptysBio, Inc. | 452.38 Million USD | -43.337% |
| Design Therapeutics, Inc. | 289.64 Million USD | -123.876% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -790.409% |
| NeurAxis, Inc. | 509.49 Thousand USD | -127170.372% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -11868.254% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1495.649% |
| Achilles Therapeutics plc | 161.45 Million USD | -301.62% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -645.685% |
| 180 Life Sciences Corp. | 5.25 Million USD | -12228.985% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -820.716% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -7474.694% |
| Nutriband Inc. | 7.51 Million USD | -8526.137% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -154.604% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -225.357% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -750.837% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1019.622% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -23.151% |
| Palisade Bio, Inc. | 14.05 Million USD | -4514.574% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -208.348% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 55.578% |
| Neurogene Inc. | 222.57 Million USD | -191.338% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -0.281% |
| AEON Biopharma, Inc. | 6.84 Million USD | -9373.192% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -43.132% |
| Sesen Bio, Inc. | 189.17 Million USD | -242.774% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -138.514% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -4629.041% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 16.904% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -142.867% |
| Athira Pharma, Inc. | 160.24 Million USD | -304.655% |
| Vaccinex, Inc. | 3.63 Million USD | -17758.441% |
| HCW Biologics Inc. | 28.51 Million USD | -2174.138% |
| XOMA Corporation | 234.3 Million USD | -176.755% |
| Nektar Therapeutics | 398.03 Million USD | -62.911% |
| Arvinas, Inc. | 1.3 Billion USD | 50.296% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3705.995% |
| Merus N.V. | 458.49 Million USD | -41.428% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -217.293% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -259.837% |
| Rezolute, Inc. | 132.73 Million USD | -388.515% |
| Clene Inc. | 52.34 Million USD | -1138.876% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -4244.983% |
| BeyondSpring Inc. | 24.8 Million USD | -2513.834% |
| Synlogic, Inc. | 75.55 Million USD | -758.293% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -5366.532% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -6824.818% |
| Peak Bio, Inc. | 2.59 Million USD | -24874.436% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -270.891% |
| Krystal Biotech, Inc. | 818.35 Million USD | 20.763% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -169.691% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 10.657% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -18027.158% |
| MannKind Corporation | 475.19 Million USD | -36.457% |
| Ikena Oncology, Inc. | 192.09 Million USD | -237.567% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -4748.512% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -456.415% |
| Gossamer Bio, Inc. | 311.91 Million USD | -107.889% |
| CohBar, Inc. | 16.36 Million USD | -3862.197% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1744.097% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -8764.525% |
| Legend Biotech Corporation | 1.84 Billion USD | 64.923% |
| Mural Oncology plc | 301.74 Million USD | -114.897% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1977.335% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -11315.383% |
| Disc Medicine, Inc. | 367.99 Million USD | -76.208% |
| Champions Oncology, Inc. | 26.13 Million USD | -2381.402% |
| REGENXBIO Inc. | 573.97 Million USD | -12.975% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -23844.596% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -320.012% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -5269.846% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -90.698% |
| Vaxart, Inc. | 91.83 Million USD | -606.131% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -982.467% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -337.169% |
| Cellectis S.A. | 334.27 Million USD | -93.987% |
| Longeveron Inc. | 12.17 Million USD | -5224.684% |
| Repare Therapeutics Inc. | 253.9 Million USD | -155.391% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 80.137% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -222.853% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 68.953% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -39804.0% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -133.495% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -297.577% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -367.364% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -2440.71% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.147% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 43.805% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -5209.594% |
| Veru Inc. | 50.59 Million USD | -1181.605% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1323.485% |
| Cingulate Inc. | 3.49 Million USD | -18472.301% |
| Passage Bio, Inc. | 150.54 Million USD | -330.728% |
| Context Therapeutics Inc. | 16.06 Million USD | -3936.921% |
| Exicure, Inc. | 11.58 Million USD | -5499.655% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -72.435% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -301.158% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -3611.31% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -94.876% |
| Nuvalent, Inc. | 732.38 Million USD | 11.462% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -4239.11% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -624.077% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -4469.375% |
| OmniAb, Inc. | 401.98 Million USD | -61.31% |
| Anew Medical, Inc. | 19.45 Million USD | -3232.862% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -2326.201% |
| Lipocine Inc. | 23 Million USD | -2719.173% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -363.811% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -112.21% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -672.493% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -433.52% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -8071.897% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 26.504% |
| Ocugen, Inc. | 64.54 Million USD | -904.601% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -420.664% |
| Q32 Bio Inc. | 306.11 Million USD | -111.826% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -15309.696% |
| Alumis Inc. Common Stock | 89.61 Million USD | -623.608% |
| Equillium, Inc. | 50.53 Million USD | -1183.277% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -762.345% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1471.08% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -38024.4% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -2380.548% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -906.254% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -17297.916% |
| Dominari Holdings Inc. | 57.55 Million USD | -1026.585% |
| Edesa Biotech, Inc. | 8.89 Million USD | -7193.68% |
| vTv Therapeutics Inc. | 11.01 Million USD | -5785.279% |
| Bio-Techne Corporation | 2.81 Billion USD | 76.95% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 30.805% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 20.089% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -133.533% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1454.937% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 2.868% |
| Nkarta, Inc. | 378.88 Million USD | -71.144% |
| BioCardia, Inc. | 2.98 Million USD | -21608.738% |
| Iterum Therapeutics plc | 26.25 Million USD | -2369.401% |